You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model

    SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION            Topic: N

    DESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Development of OCT Imaging Adapter for Interstitial Tissue Imaging

    SBC: WEST FACE MEDICAL DEVICES, INC.            Topic: NIBIB

    DESCRIPTION provided by applicant This Phase I STTR Grant Proposal requests $ support for WestFace Medical Device to construct and test the WestFace Imaging Adaptor in conjunction with Ruikang K Wang PhD and his laboratory at the University of Washington Utilizing optical coherence tomography OCT the patented OCT Adaptor USPTO Pats provides r ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Retinoids as Novel Treatment of Ischemic Stroke

    SBC: ACRYMED, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Stroke is the third leading cause of death in the U.S. and a major source of disability. Ischemic stroke, the most common type, is associated with a dramatic increase in calcium influx in brain tissue, an increased production in reactive oxygen species (ROS), cell death and inflammation. Studies by the PI have shown that retinoids block neuronal voltage-gated c ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  4. An Epithermal Neutron Source for Cancer Therapy

    SBC: ADELPHI TECHNOLOGY INC            Topic: N/A

    DESCRIPTION (provided by applicant): We propose to develop a commercial neutron source for the treatment of brain and liver cancer based on boron neutron capture therapy (BNCT). Boron-containing compounds are injected into a patient's bloodstream and accumulate in a malignant tumor. When irradiated with neutrons, the boron atoms preferentially capture neutrons and decay, releasing short-range radi ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  5. Study of CdZnTe Electrode Interface and Fabrication Technology Development

    SBC: Aguila Technologies, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): In several recent PA's, the NIH has articulated a clear vision for the future of medical imaging systems a) enhanced spatial or temporal resolution, b) better sensitivity and specificity, c) multi-modality, and d) new functional or molecular imaging or spectroscopy methods. Owing to their unique combination of properties, direct conversion gamma radiation imagi ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  6. New APEX diagnostic for hereditary sensorineural hearing loss

    SBC: APEX DX, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): In developed countries, approximately 1:1000 children are born deaf and approximately 1:300 children are born with some lesser degree of hearing loss. At least 50% of the deafness and hearing impairment is likely to be attributable to genetic factors, with a large number of genes involved in the pathogenesis. The molecular genetic basis for the majority of case ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  7. Safety of intraarticular N-acetylglucosamine

    SBC: ARTYX PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the most prevalent joint disease, causing joint pain and dysfunction. OA is also associated with substantial co-morbidity and reduces life expectancy. Pharmacologic therapy is limited to symptom modification and disease-modifying therapies are currently not available. Furthermore, even symptom-modifying therapies are limited in efficacy a ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  8. Stem Cells for Neonatal Hypoxic-Ischemic Brain Injury

    SBC: ATHERSYS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The emergence of technologies enabling isolation of adult stem cells has allowed evaluation of cell therapeutics for central nervous system disorders with a path for clinical development. Much promise has been shown using stem cells in acute disease models such as stroke or hypoxic injury to the brain, and as well to chronic degenerative diseases such as Park ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  9. Mobile Training of Skilled Support Personnel

    SBC: BANDEMAR NETWORKS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant) Skilled Service Personnel (SSP) support emergency response organizations during an emergency incident involving weapons of mass destruction and include laborers, operating engineers, carpenters, ironworkers, sanitation workers and utility workers. SSP called to an emergency incident rarely have recent detailed training on the chemical, biological, radiological, ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  10. New Opioids for Alcoholism

    SBC: BEHAVIORAL PHARMA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Highly potent, orally active, metabolically stable, long-lived opioid agents for the treatment of alcoholism that have decreased side effects such as nausea, addiction liability, immunosuppression and respiratory depression represents a great unmet need. While a mu opioid receptor antagonist is currently approved by the FDA for alcoholism, it possesses several ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government